Marine drugs for cancer: surfacing biotechnological innovations from the oceans

Detalhes bibliográficos
Autor(a) principal: Jimenez, Paula Christine
Data de Publicação: 2019
Outros Autores: Wilke, Diego Veras, Costa-Lotufo, Leticia Veras
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/154758
Resumo: This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources.
id USP-19_c49bfbc86d99115ca656fc0a819ca6fb
oai_identifier_str oai:revistas.usp.br:article/154758
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Marine drugs for cancer: surfacing biotechnological innovations from the oceansAnticancer Drug DevelopmentMarine BiotechnologyAntibody-Drug ConjugatesAntimetabolites DrugsAnti-tubulin DrugsDNA-Alkylating AgentsThis review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-02-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/15475810.6061/clinics/2018/e482sClinics; v. 73 n. Suppl. 1 (2018); e482sClinics; Vol. 73 Núm. Suppl. 1 (2018); e482sClinics; Vol. 73 No. Suppl. 1 (2018); e482s1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/154758/150781Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessJimenez, Paula ChristineWilke, Diego VerasCosta-Lotufo, Leticia Veras2019-05-14T11:48:25Zoai:revistas.usp.br:article/154758Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-14T11:48:25Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Marine drugs for cancer: surfacing biotechnological innovations from the oceans
title Marine drugs for cancer: surfacing biotechnological innovations from the oceans
spellingShingle Marine drugs for cancer: surfacing biotechnological innovations from the oceans
Jimenez, Paula Christine
Anticancer Drug Development
Marine Biotechnology
Antibody-Drug Conjugates
Antimetabolites Drugs
Anti-tubulin Drugs
DNA-Alkylating Agents
title_short Marine drugs for cancer: surfacing biotechnological innovations from the oceans
title_full Marine drugs for cancer: surfacing biotechnological innovations from the oceans
title_fullStr Marine drugs for cancer: surfacing biotechnological innovations from the oceans
title_full_unstemmed Marine drugs for cancer: surfacing biotechnological innovations from the oceans
title_sort Marine drugs for cancer: surfacing biotechnological innovations from the oceans
author Jimenez, Paula Christine
author_facet Jimenez, Paula Christine
Wilke, Diego Veras
Costa-Lotufo, Leticia Veras
author_role author
author2 Wilke, Diego Veras
Costa-Lotufo, Leticia Veras
author2_role author
author
dc.contributor.author.fl_str_mv Jimenez, Paula Christine
Wilke, Diego Veras
Costa-Lotufo, Leticia Veras
dc.subject.por.fl_str_mv Anticancer Drug Development
Marine Biotechnology
Antibody-Drug Conjugates
Antimetabolites Drugs
Anti-tubulin Drugs
DNA-Alkylating Agents
topic Anticancer Drug Development
Marine Biotechnology
Antibody-Drug Conjugates
Antimetabolites Drugs
Anti-tubulin Drugs
DNA-Alkylating Agents
description This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources.
publishDate 2019
dc.date.none.fl_str_mv 2019-02-14
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/154758
10.6061/clinics/2018/e482s
url https://www.revistas.usp.br/clinics/article/view/154758
identifier_str_mv 10.6061/clinics/2018/e482s
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/154758/150781
dc.rights.driver.fl_str_mv Copyright (c) 2019 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; v. 73 n. Suppl. 1 (2018); e482s
Clinics; Vol. 73 Núm. Suppl. 1 (2018); e482s
Clinics; Vol. 73 No. Suppl. 1 (2018); e482s
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1787713180664856576

Registros relacionados